COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM
First Claim
1. A composition for the treatment of or prevention of Alzheimer'"'"'s disease or mild cognitive impairment, comprising:
- i) medium chain triglycerides (MCT) of the formula;
wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbon chains in an amount effective for the treatment of or prevention of loss of cognitive function in a mammal caused by reduced neuronal metabolism in dementia of Alzheimer'"'"'s type or mild cognitive impairment; and
ii) a therapeutic agent selected from the group consisting of anti-Alzheimer'"'"'s agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer'"'"'s type, mild cognitive impairment, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability, and a therapeutic agent selected from the group consisting of anti-Alzheimer'"'"'s agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof. Preferred therapeutic agents include donepezil, rivastigmine, galantamine, and memantine.
-
Citations
31 Claims
-
1. A composition for the treatment of or prevention of Alzheimer'"'"'s disease or mild cognitive impairment, comprising:
-
i) medium chain triglycerides (MCT) of the formula;
wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbon chains in an amount effective for the treatment of or prevention of loss of cognitive function in a mammal caused by reduced neuronal metabolism in dementia of Alzheimer'"'"'s type or mild cognitive impairment; and
ii) a therapeutic agent selected from the group consisting of anti-Alzheimer'"'"'s agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method of treating dementia of Alzheimer'"'"'s type or mild cognitive impairment, comprising the steps of:
-
(a) identifying a mammal having, or at risk of dementia of Alzheimer'"'"'s type or mild cognitive impairment;
(b) administering to the mammal a first composition comprising medium chain triglycerides (MCT) of the formula;
wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbon chains in an amount effective for the treatment of or prevention of loss of cognitive function caused by reduced neuronal metabolism in dementia of Alzheimer'"'"'s type or mild cognitive impairment; and
(c) administering to the mammal a second composition comprising a therapeutic agent selected from the group consisting of anti-Alzheimer'"'"'s agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
-
-
31. A liquid dosage form for oral consumption comprising:
-
i) a unit dose of MCT sufficient to a) raise blood levels of D-β
-hydroxybutyrate to about 0.1 to about 5 mM or b) raise urinary excretion levels of D-β
-hydroxybutyrate to about 5 mg/dL to about 160 mg/dL;
a plurality of vitamins;
flavoring, and a carbohydrate source and wherein the MCT are of the formula;
wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having carbon chains of 5-12 carbons; and
ii) a therapeutic agent selected from the group consisting of anti-Alzheimer'"'"'s agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof.
-
Specification